Molecular Devices

Founded in 1983 and headquartered in San Jose, USA, Molecular Devices is a well-established, revenue-generating private company operating in the life sciences tools and diagnostics sector. Its core business model revolves around providing a platform of advanced hardware and software instruments—including microplate readers, high-content imaging systems, and automated workcells—that are essential for drug discovery, basic research, and therapeutic validation. The company is strategically focused on key growth areas such as complex cell models (e.g., organoids), the integration of AI/ML into imaging and analysis, and supporting next-generation therapeutic modalities. With a partnership-oriented approach, Molecular Devices aims to streamline laboratory workflows and enhance data integrity for its global customer base in academia, pharma, and biotech.

Integrated ecosystem of bioanalytical instruments and software, including multi-mode microplate readers, high-content imaging systems with AI, microbial colony pickers, lab automation workcells, and GxP-compliant data analysis software.

Molecular Devices competes in a crowded and competitive market with major players like Agilent Technologies, Thermo Fisher Scientific, PerkinElmer, and BioTek (part of Agilent). Differentiation is achieved through deep application expertise, a focus on integrated AI-powered imaging workflows, a strong reputation in microplate reading, and its position as a Danaher company, which provides operational and financial scale.